# Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)

> **NCT02701634** · PHASE2 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 66 (actual)

## Conditions studied

- Chronic Graft Versus Host Disease

## Interventions

- **DRUG:** ENTO
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02701634
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-05-27
- **Primary completion:** 2017-12-19
- **Final completion:** 2018-03-06
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2018-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02701634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02701634, "Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02701634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*